GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spyre Therapeutics Inc (NAS:SYRE) » Definitions » E10

Spyre Therapeutics (Spyre Therapeutics) E10 : $-52.22 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Spyre Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Spyre Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was $-1.200. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-52.22 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-06), Spyre Therapeutics's current stock price is $33.61. Spyre Therapeutics's E10 for the quarter that ended in Mar. 2024 was $-52.22. Spyre Therapeutics's Shiller PE Ratio of today is .


Spyre Therapeutics E10 Historical Data

The historical data trend for Spyre Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spyre Therapeutics E10 Chart

Spyre Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -51.89

Spyre Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -51.89 -52.22

Competitive Comparison of Spyre Therapeutics's E10

For the Biotechnology subindustry, Spyre Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spyre Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's Shiller PE Ratio falls into.



Spyre Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Spyre Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.2/131.7762*131.7762
=-1.200

Current CPI (Mar. 2024) = 131.7762.

Spyre Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201406 -8.783 100.560 -11.510
201409 -11.913 100.428 -15.632
201412 -11.661 99.070 -15.511
201503 -9.883 99.621 -13.073
201506 -5.231 100.684 -6.846
201509 -12.511 100.392 -16.422
201512 -8.721 99.792 -11.516
201603 -9.945 100.470 -13.044
201606 -11.500 101.688 -14.903
201609 -11.750 101.861 -15.201
201612 -8.250 101.863 -10.673
201703 -11.750 102.862 -15.053
201706 -11.750 103.349 -14.982
201709 -12.000 104.136 -15.185
201712 -9.500 104.011 -12.036
201803 -12.250 105.290 -15.332
201806 -11.500 106.317 -14.254
201809 -13.500 106.507 -16.703
201812 -16.000 105.998 -19.891
201903 -14.750 107.251 -18.123
201906 -13.750 108.070 -16.766
201909 -16.500 108.329 -20.071
201912 -16.250 108.420 -19.751
202003 -14.250 108.902 -17.243
202006 -10.000 108.767 -12.115
202009 -7.250 109.815 -8.700
202012 -8.500 109.897 -10.192
202103 -7.000 111.754 -8.254
202106 -2.500 114.631 -2.874
202109 -7.750 115.734 -8.824
202112 -7.770 117.630 -8.704
202203 -9.250 121.301 -10.049
202206 -6.750 125.017 -7.115
202209 -4.840 125.227 -5.093
202212 -4.690 125.222 -4.935
202303 -4.890 127.348 -5.060
202306 -56.750 128.729 -58.093
202309 -9.340 129.860 -9.478
202312 -1.752 129.419 -1.784
202403 -1.200 131.776 -1.200

Add all the adjusted EPS together and divide 10 will get our e10.


Spyre Therapeutics  (NAS:SYRE) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Spyre Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Spyre Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Spyre Therapeutics (Spyre Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
221 Crescent Street, Building 23,, Suite 105, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
Executives
Scott L Burrows officer: Chief Financial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Heidy King-jones officer: See Remarks C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Fairmount Healthcare Co-invest L.p. director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Peter Evan Harwin director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Cameron Turtle officer: Chief Operating Officer C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Michael Thomas Henderson director 421 KIPLING STREET, PALO ALTO CA 94301
Fairmount Healthcare Fund L.p. director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Healthcare Fund Ii L.p. director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Tomas Kiselak director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jeff Marc Goldberg director, officer: President and CEO C/O AKCEA THERAPEUTICS, 55 CAMBRIDGE PARKWAY, STE 100, CAMBRIDGE MA 02142
Linda L Neuman officer: Chief Medical Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746
Marcio Souza director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
James Paul Kastenmayer officer: Interim CEO & General Counsel ONE MEDIMMUNE WAY, FLOOR ONE, AREA TWO, GAITHERSBURG MD 20879
Hanley Jr. Michael Conick officer: Chief Commercial Officer C/O AEGLEA THERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746